| Rheumatoid Arthritis

Abrilada vs Celebrex

Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.

Deep comparison between: Abrilada vs Celebrex with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsCelebrex has a higher rate of injection site reactions vs Abrilada based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Celebrex but not Abrilada, including UnitedHealthcare

Category

Abrilada

Celebrex

At A Glance

RouteSC injection

FrequencyEvery 1-2 weeks

ClassTNF-alpha blocker

RouteOral

FrequencyOnce or twice daily

ClassCOX-2 inhibitor

Indications

Rheumatoid Arthritis
Juvenile polyarthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Psoriasis vulgaris
Hidradenitis Suppurativa
Uveitis

Degenerative polyarthritis
Rheumatoid Arthritis
Juvenile rheumatoid arthritis
Ankylosing spondylitis
Primary dysmenorrhea

Dosing

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.

Juvenile polyarthritis Weight-based SC dosing every other week for patients 2 years of age and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (>=30 kg).

Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction then 20 mg every other week (<40 kg) or 40 mg every other week (>=40 kg) starting Day 29.

Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Week 8 (Day 57).

Psoriasis vulgaris, Uveitis 80 mg SC initial dose, then 40 mg every other week starting one week after the initial dose.

Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Degenerative polyarthritis 200 mg once daily or 100 mg twice daily, oral.

Rheumatoid Arthritis 100 mg to 200 mg twice daily, oral.

Juvenile rheumatoid arthritis 50 mg twice daily for patients 10-25 kg; 100 mg twice daily for patients >25 kg, oral.

Ankylosing spondylitis 200 mg once daily or 100 mg twice daily, oral; if no effect after 6 weeks, may trial 400 mg daily.

Primary dysmenorrhea 400 mg initially, followed by 200 mg if needed on day 1; 200 mg twice daily on subsequent days, oral.

Contraindications

—

Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib or any components of the drug product
History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
Setting of CABG surgery
Demonstrated allergic-type reactions to sulfonamides

Drug Interactions

1222View drug interactions

1343View drug interactions

Adverse Reactions

Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, nausea, urinary tract infection, sinusitis, hyperlipidemia, flu syndrome, abdominal pain, back pain, hypercholesterolemia, hypertension

Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, malignancies, hepatitis B reactivation, demyelinating disorders, hematologic reactions, heart failure, autoimmunity

Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, systemic vasculitis, deep vein thrombosis

Most common (>=2%) Headache, dyspepsia, upper respiratory infection, diarrhea, sinusitis, abdominal pain, nausea, back pain, peripheral edema, rhinitis, pharyngitis, rash, flatulence, dizziness, insomnia.

Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity.

Postmarketing Vasculitis, deep venous thrombosis, angioedema, liver necrosis, hepatic failure, agranulocytosis, aplastic anemia, pancytopenia, aseptic meningitis, fatal intracranial hemorrhage, interstitial nephritis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, AGEP, fixed drug eruption.

Pharmacology

Adalimumab-afzb is a recombinant human IgG1 monoclonal antibody TNF-alpha blocker that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammation and modulating TNF-induced biological responses including leukocyte migration.

Celecoxib is a selective COX-2 inhibitor that reduces prostaglandin synthesis in peripheral tissues and the CNS, producing analgesic, anti-inflammatory, and antipyretic effects; at therapeutic doses it does not inhibit platelet aggregation or prolong bleeding time.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Abrilada